Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Transplant for Hematologic Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~1. Diagnosis of myelodysplastic disorders; Fanconi's Anemia; Acute Myelogenous Leukemia (including secondary); Acute Lymphoblastic Leukemia; Multiple Myeloma; Plasma Cell Dyscrasia; lymphoproliferative disorders (Non-Hodgkin Lymphoma, Hairy Cell Leukemia, Chronic Lymphocytic Leukemia, and Hodgkin's Disease). Diagnosis of myelodysplastic disorders which is not good risk by IPSS: Fanconi's Anemia; Acute Myelogenous Leukemia (1st or subsequent relapse, or 2nd or subsequent CR, or refractory disease); Acute Lymphoblastic Leukemia in 2nd or subsequent remission or relapse or refractory disease; Philadelphia Chromosome-positive Chronic Myelogenous Leukemia (failed STI and interferon); Multiple Myeloma (Stage II or III); Lymphoma; Chronic Lymphocytic Leukemia (primary refractory or recurrent disease); Hodgkin's Disease (after relapse); Hemophagocytic Lymphohistiocytosis (failed chemotherapy and/or anti-viral therapy); bone marrow failure such as Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria; PNH (failed prior therapies).~2. Conditions that increase treatment related mortality: (need one or more to be eligible): Age \> / = 50 years; EF of less than 45%; DLCO less than 50% or FEVI 50-75% of predicted value; Diabetes Mellitus; Renal Insufficiency (but creatinine clearance not less than 25 mL/min); Prior recent history of systemic fungal infection; 3rd or greater remission of AML or ALL; Significant Grade III or IV neurologic or hepatic toxicity from previous treatment; More than 1 year from diagnosis (CML or Myeloma patients ONLY); Multiple types of treatment regimens (equal to or more than 3); Significant Grade III or IV neurologic or hepatic toxicity from previous treatment; Prior autologous or allogeneic stem cell transplantation.~3. Haploidentical family member donor. This protocol is open to patients who lack a 5/6 or 6/6 HLA antigen-matched donor. Due to the increased risk of GvHD, patients with Fanconi Anemia and a 5/6 HLA match will also be eligible.~   For this protocol, the best donor will be defined as a first-degree haploidentical family member who matches at the greatest number of MHC loci. Matching will be determined by Class I and Class II DNA typing. The donor should be sufficiently healthy as to not be at increased risk from the stem cell mobilization procedure. Should more than one equally MHC-incompatible donor be identified, other selection criteria will include: age and size of donor, CMV status, and sex. The Principal Investigator will make final decisions.~4. Available healthy donor without any contraindications for donation.~5. Patient and/or legal representative and/or legal guardian able to understand and sign consent.~6. Age between birth and 70 years.~7. Women of child-bearing potential must have a negative pregnancy test.~EXCLUSION CRITERIA:~1. Pregnant, lactating or unwilling to use contraception.~2. HIV-positive patient.~3. Uncontrolled intercurrent infection.~4. Untreated blast crisis for CML.~5. Uncontrolled high-grade lymphoproliferative disease / lymphoma.~6. Unstable angina and uncompensated congestive heart failure (Zubrod of 3 or greater).~7. Severe chronic pulmonary disease requiring oxygen (Zubrod of 3 or greater).~8. Hemodialysis dependent.~9. Active hepatitis or cirrhosis with total bilirubin, SGOT, and SGPT greater than 3X upper limit of normal.~10. Unstable cerebral vascular disease and recent hemorrhagic stroke (less than 6 months).~11. Active CNS disease from hematological disorder.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Stem Cell Transplant (Type: EXPERIMENTAL): Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.

Based on this trial design, predict the completion outcome and termination type (if applicable).